Trabecular meshwork (TM) cells are the governing regulators of the TM structure. When the functionality of these cells is impaired, the structure of the TM is perturbed which often results in increased ocular hypertension. High intraocular pressure is the most significant risk factor for steroid-induced glaucoma. Dexamethasone (Dex)-induced phenotype of TM cells is widely utilized as a model system to gain insight into mechanisms underlying damaged TM in glaucoma. In this study, to assess the possible role of abnormal Wnt signaling in steroid-induced glaucoma, we analyzed the effects of small-molecule Wnt signaling modulators on Dex-induced expression extracellular matrix proteins of primary human TM cells. While Dex-treated TM cells exhibited increased collagen and fibronectin expression, we found that Wnt signaling inhibitor 3235-0367 suppressed these Dex-induced effects. We therefore propose that Wnt signaling plays an important role in Dexmediated impairment of TM cell functions. Moreover, the use of small-molecule Wnt signaling inhibitors to treat TM cells may provide an opportunity of restoring TM tissue in steroid-induced glaucoma.
Introduction
Glaucoma is a leading cause of blindness in the world, and one of its causative factors is increased intraocular pressure (IOP). Increased IOP is a risk factor commonly found in patients with glaucoma caused by prolonged steroid treatment [1, 2] . The flow of aqueous humor through Schlemm's canal is regulated by the trabecular meshwork (TM). When the TM becomes occluded, the flow of aqueous humor is hampered resulting in increased IOP. Ocular hypertension from the pressure can potentially damage the optic nerve, resulting in steroid-induced glaucoma [3] .
TM cells are the predominant regulators of the structural integrity of the TM. The glaucomatous phenotypes of TM cells consistent with decreased outflow facility include: increased deposition of extracellular matrix (ECM) including collagen [4] [5] [6] and fibronectin [4] [5] [6] [7] [8] , and increased cell stiffness [9] . However, the signaling mechanisms underlying this TM cell dysfunction are largely unknown. It has been established that dexamethasone (Dex) induces aberrant levels of myocilin [10] , fibronectin [8, 11] , and collagen in TM cells [11] .
Indeed, Dex-induced glaucomatous phenotypes of TM cells have been widely used as a model to study TM cell dysfunction in glaucoma [12] [13] [14] .
Abnormal Wnt signaling has been implicated in glaucoma. For example, the expression of sFRP1, a Wnt signaling antagonist, is upregulated in glaucomatous TM cells [15] , and the correlation of sFRP1 upregulation and increased IOP in both organ culture models and mice has been demonstrated [15] . The presence of active Wnt signaling has also been reported on a cellular level in vitro within TM cells [16, 17] . This active Wnt signaling is found to be involved in TM cell mediated ECM expression [18] and TM cell stiffening [19] . Overall, Wnt signaling appears to be a key player in TM regulation, with strong evidence suggesting that abnormal Wnt signaling may promote IOP [15] . Therefore, we decided to investigate whether a small-molecule Wnt signaling activator, BML-284 [20] , or a small-molecule Wnt signaling inhibitor, 3235-0367 [21] , can affect the Dex-induced glaucomatous phenotype of TM cells. We found that the inhibition of Wnt signaling abrogated Dex-mediated myocilin expression and ECM expression of primary human TM cells. This data reveals that Wnt . The mRNA expression data were obtained from three independent experiments (*p < 0.05 via One-way ANOVA with Dunnett's correction) and the raw immunofluorescence images are shown in the Supplementary Fig. S1 .
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signaling may exhibit pleiotropic roles in glaucomatous TM. In addition to deciphering the mechanism of Wnt signaling in TM cell dysfunction, small-molecule Wnt signaling inhibitors may have potential therapeutic applications within steroid-induced glaucoma.
Material and methods

Primary human TM cells
Three independent human primary TM cell cultures were established from three donors at ScienCell Research Laboratories, Inc. (Carlsbad, CA). The first TM cell culture (HTM1; ScienCell catalog number 6590, lot number 4973) was obtained from a 25-year-old Caucasian male donor. The second TM cell culture (HTM2; ScienCell catalog number 6590, lot number 5975) was obtained from a 24-weekold female fetus. The third TM cell culture (HTM3; ScienCell catalog number 6590, lot number 5987) was obtained from a 22-week-old female fetus. All experiments involving human tissue/cells were performed in compliance with the tenets of the Declaration of Helsinki. Internal review board approval was obtained for the procurement and use of human eye tissue for the study. Briefly, the eyes were rinsed with serum-free Dulbecco's minimum essential medium (DMEM) three times. Under a dissecting microscope, a small incision was made 1.5 mm posterior to the limbus. Using vannas straight capsulotomy scissors, the incision was extended 360 degrees to remove the anterior portion of the eye. The iris and ciliary body were carefully removed using Precision Watchmaker's Extra-Fine Point forceps, taking care to avoid damage to the angle area. Using a surgical blade, a thin layer (1.5 mm×0.5 mm) of light gray TM tissue was cut from the angle area. The dissected TM tissues were further cut into smaller pieces, rinsed with serum-free DMEM, resuspended in fetal bovine serum (FBS), and plated as explants in a T-75 flask. The flask was left in the hood for TM tissue attachment, after which TM cell medium (ScienCell, Carlsbad, CA) was added. Cells were cultured at 37°C, until day 7, when a monolayer of cells around the tissue blocks was harvested and frozen in cell freezing medium (ScienCell, Carlsbad, CA) as passage zero. The cells were maintained in DMEM low glucose (Thermo Fisher, Waltham, MA) with 10% FBS (VWR, Radnor, PA), 1% amino acids (Thermo Fisher, Waltham, MA), and 1% TM cell growth supplement (ScienCell, Carlsbad, CA). Cells from passages 3-5 were used for all assays.
Compound preparation and treatment
Dex (Sigma-Aldrich, St. Louis, MO), Wnt signaling inhibitor 3235-0367 (ChemDiv, San Diego, CA), and Wnt signaling activator BML-824 (Santa Cruz Biotechnology, Dallas, TX) were dissolved in 100% DMSO (Sigma-Aldrich, St. Louis, MO). Dex and small-molecule Wnt signaling modulators were applied with the working concentrations of 1 µM and 0.1 µM (individual final DMSO content of 0.001%, therefore the vehicle control used was 0.002% given that Dex was added together with the compound in some conditions). These concentrations were chosen after a viability assessment was carried out for cells treated with concentrations ranging from 0.1 to 50 µM. Compounds were added every 24-h, and the cells were treated for seven days before harvesting for PCR analysis.
Quantitative PCR
Total mRNA was isolated from cells using the Qiagen RNeasy mini kit (Qiagen, Valencia, CA) as per manufacturer's protocol. The concentration of RNA was analyzed using a NanoDrop (Thermo Fisher, Waltham, MA). The Quantitect (Qiagen, Germantown, MD) reverse transcriptase process was utilized as per manufacturer's protocol to obtain cDNA. Quantitative PCR was carried out using the Realplex2 (Eppendorf, Hauppauge, NY) with TaqMan primers for human GAPDH (Hs02758991_g1), human AXIN2 (AXIN2, Hs00610344_m1), human myocilin (MYOC, Hs00165345_m1), human collagen I (COL1A1, Hs00164004_m1), human collagen IV (COL4A1, Hs00266237_m1), and human fibronectin (FN1, Hs01549976_m1). Gene expression was normalized against the expression of GAPDH. We followed the manufacturer's protocol for the qPCR reaction and utilized the deltadelta method of analysis. Each experimental condition was repeated at least three times.
Immunofluorescence
Cells grown to 90% confluency on CC2 glass chamber slides (Thermo Fisher, Waltham, MA) were treated with Dex (0.1 µM), Dex with compound or DMSO (vehicle) for seven days. Cells were washed once with PBS (Thermo Fisher, Waltham, MA) and fixed in 4% paraformaldehyde (SigmaAldrich, St. Louis, MO) for 30 min at room temperature. Samples were washed 3 times for 5 min per wash with PBS. Samples were blocked with PBS containing 5% goat serum and 0.25% Triton-X-100. The following primary antibodies were used: rabbit anti-human myocilin (Santa Cruz, Dallas, TX), rabbit anti-human collagen I (34710, Abcam, Cambridge, MA), rabbit anti-human collagen IV (6586, Abcam, Cambridge, MA), rabbit antihuman fibronectin (2413, Abcam, Cambridge, MA), and phalloidin-TRITC (Sigma-Aldrich, St. Louis, MO) was added and incubated overnight at 4°C in PBS containing 1% goat serum. Samples were washed once with PBS. Secondary antibodies including, goat anti-rabbit Alexafluor 488 (A-11034, Thermo Fisher, Waltham, MA) or goat anti-rabbit Alexafluor 594 (A-11037, Thermo Fisher, Waltham, MA), were added to the membrane and incubated for one hour at room temperature. The samples were washed 3 times for 5 min per wash, with PBS and then counterstained and mounted with DAPI (Vector Labs, Burlingame, CA). Samples were visualized using a Keyence BZ-X700 fluorescence microscope (Keyence, Japan) and the acquisition settings were identical for all treatments. Protein expressions were quantified from 488 or 594 fluorescence images by using the software package Image J. Specifically, after splitting the DAPI channel and the 488 channel (or the 594 channel), calculations of the area covered by the fluorescence from the 488 (or 594 channel) were carried out and normalized against the area detected in the DAPI channel. There were three random fields of views photographed for each quantification. 
TM cell collagen secretion
Collagen secreted into the media by the TM cultures was analyzed using the Sircol Assay Kit (Biocolor, Westbury) as per manufacturer's protocol. First, the TM cells were seeded into a 6-well plate at 2.0×10 5 cells/well and incubated for 4-h. Then, the media was replaced with conditioned media either containing Dex (0.1 µM), Dex with compound, or DMSO (vehicle), and then incubated at 37°C for 48-h. After incubation, 1 mL of media was collected from each tube, mixed with 200 µL of Collagen Isolation and Concentration Reagent from the Sircol Assay Kit, and incubated overnight at 4°C. The following day, the samples were centrifuged at 12,000 rpm for 10 min and the supernatants were discarded. Then, 1 mL of Sircol dye reagent (Sircol Assay Kit) that binds to collagen was added to each tube and gently mixed by inverting. The tubes were incubated for 30 min at room temperature and were then centrifuged at 12,000 rpm for 10 min. After, 750 µL/tube of ice cold Acid-Salt Wash (from the Sircol Assay Kit) was gently layered over the collagen-dye pellet, mixed, and centrifuged at 12,000 rpm for 10 min to remove any unbound dye. The supernatant was discarded and 250 µL/tube of the alkali reagent was added to the collagen-bound dye. The pellet formed was vortexed until it completely dissolved back into solution and 200 µL aliquots of each sample was loaded on a 96-well plate. Using the FilterMax F5 microplate reader (Molecular Devices, Sunnyvale, CA), absorbance was measured at 555 nm.
Western blot analysis
Cells were treated with Dex for five days and then lysed in RIPA lysis buffer (25 mM Tris, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% SDS). The lysis buffer was supplemented with protease and phosphatase inhibitor cocktails (Thermofisher Scientific). The BCA assay (Pierce, Fisher Scientific) was used to quantify protein.
Proteins were separated by molecular weight using SDS polyacrylamide gel electrophoresis, transferred onto a PVDF membrane (Bio-Rad Laboratories, Inc. Hercules, CA), and probed against myocilin and β-Actin (loading control) (Santa Cruz Biotechnology, Santa Cruz, CA).
Statistical analysis
Prism software (GraphPad Software Inc., San Diego, CA) was utilized for statistic analysis where One-way ANOVA was used together with Dunnett's correction to obtain the standard error of the mean and significance (p < 0.05 was considered significant). 
Results
TM cell characterization
In this study, we used TM cells from a 25-year-old donor and two human fetal donors since TM cells from younger donors have increased and consistent doubling rates, as well as greater passage capacity [22, 23] . The morphology of the cells we used in our study was similar to that reported by Rhee et al. [24] , Morgan et al. [19] , and Lin et al. [22] , where they were small in size, slightly elongated, exhibited a moderate to low number of processes, and had cell bodies that were both rounder and wider than those of scleral fibroblasts. The predominant marker of TM cells is increased myocilin expression following treatment with Dex [10, 25, 26] . We found that both the level of myocilin protein expression (Fig. 1A , B, and D) and of MYOC mRNA (Fig. 1C) were increased in the TM cells following Dex treatment. The protein expression profile of these cells, including the increased myocilin expression levels after Dex treatment, is similar to that of reported TM cells [22] .
Dex induced myocilin expression in primary human TM cells is decreased with Wnt signaling inhibition
A known Wnt signaling antagonist, sFRP1, is upregulated in glaucomatous TM [15] . Given that Dex-mediated phenotype of TM cells is consistent with that of glaucomatous TM [8, 11, 17, [27] [28] [29] , we speculated that activation of Wnt signaling would alleviate Dexmediated TM cell activity. Hence, we examined whether Wnt signaling activator, BML-284 [20] , would counteract the effects of Dex upon myocilin expression of the cells. We chose Wnt signaling activator BML-284 because this compound activates Wnt signaling without inhibiting GSK-3β [20] . Though most of the known Wnt signaling activators activate Wnt signaling by inhibiting GSK-3β, a key element in the canonical Wnt signaling pathway, it has been suggested that the compound BML-284 may be able to activate both canonical and noncanonical Wnt signaling pathways [20] . We treated the Dexinduced TM cells with BML-284 and a Wnt inhibitor, 3235-0367, as a control. We chose compound 3235-0367 to inhibit Wnt signaling because this compound targets the interactions between the Wnt protein and its cell-surface receptor, Frizzled [21] ; therefore, it is considered a "broad-spectrum" Wnt signaling inhibitor that can block both canonical and non-canonical Wnt signaling pathways. To our surprise, we found that BML-284 maintained the level of Dex-mediated myocilin expression, and that inhibition of Wnt signaling with 3235-0367 prevented Dex-induced myocilin expression (Fig. 2) . Furthermore, BML-284 alone increased myocilin expression of the TM cells, but this was not the case when the cells were treated with both BML-284 and 3235-0367. Collectively, these data suggest that Wnt signaling promotes myocilin expression in TM cells, and Dex induces myocilin expression in a Wnt signaling-dependent manner.
Dex-mediated AXIN2 expression is decreased with Wnt signaling inhibition
One of the known Wnt signaling target genes is AXIN2 [30, 31] . Whereas most Wnt signaling target genes are tissue or developmental stage-specific, the AXIN2 gene is considered a global transcriptional target [32] . For this reason, AXIN2 is widely regarded as a general indicator of Wnt signaling pathway activity [33] . Therefore, to determine whether Dex directly activated Wnt signaling, we examined the expression of AXIN2 in the Dex-treated cells. We found that AXIN2 expression was increased in the TM cells treated with Dex (Fig. 3) and that when the TM cells received Dex together with 3235-0367, the AXIN2 expression was not altered beyond control level. Additionally, BML-284 increased AXIN2 expression in the TM cells; however, this expression was at control level when BML-284 was added to the cells with 3235-0367. Overall, these findings suggest that Dex directly activates Wnt signaling and that small molecule modulators BML-284 and 3235-0367 can activate or inhibit Wnt signaling in the TM cells, respectively.
Extracellular matrix expression in primary human TM cells treated with Dex is decreased with Wnt signaling inhibition
Glaucomatous TM phenotypes that are consistent with decreased outflow include aberrant accumulations of ECM components such as collagen [4] [5] [6] and fibronectin [4] [5] [6] [7] [8] 11] , as well as abnormal ECM structural remodeling [34] [35] [36] . Dex is known to increase expression of collagen [11] and fibronectin [8, 11] in TM cells, and to change the ECM structural organization [34] [35] [36] . The mechanisms underlying how Dex orchestrates this profibrotic activity in TM cells is vastly unknown; however, it has been shown that expression of ECM proteins is regulated by Wnt signaling [18] . Therefore, using 3235-0367 and BML-284, we decided to examine whether Wnt signaling was involved in the Dex-mediated expression of ECM components in primary human TM cells. We first confirmed that Dex increased mRNA and protein expression of collagen I (Fig. 4A-C ) and collagen IV (Fig. 4D-F) . Furthermore, as previously reported [8, 11] , the expression of fibronectin mRNA and protein was increased upon Dex treatment (Fig. 5) . We then found that Wnt signaling inhibitor 3235-0367 abolished this Dex-mediated increase of collagen and fibronectin expression. Intriguingly, Wnt signaling activator BML-284 alone also increased the expression of collagen I and collagen IV; however, their expression level were reverted back to normal when the Wnt signaling inhibitor 3235-0367 was added together with BML-284 into the TM cells. Overall, these data indicate that, in the Dex-treated TM cells, Wnt signaling plays a role in the aberrant collagen and fibronectin expression.
Besides upregulated collagen expression in the Dex-treated TM cells, we also found that within 48 h after Dex treatment, secretion of collagen from the Dex-treated TM cells was also upregulated (Fig. 6) . Moreover, consistent with our collagen expression study, Wnt signaling effectively abrogated the unregulated collagen secretion induced by the Dex-treatment. Also, when the TM cells were treated with BML-284, the Wnt signaling activator used in our study as a control, we found that collagen secretion was elevated (Fig. 6 ). These data further suggest that aberrant Wnt signaling activity in the TM cells may also increase collagen secretion.
Discussion
TM cells are the governing regulators of the structural integrity of TM. When the functionality of these cells is impaired, the TM becomes occluded, and the flow of aqueous humor is hampered, ultimately resulting in ocular hypertension. The underlying mechanism of glaucomatous TM is largely unknown; however, Wnt signaling pathways have been implicated in glaucomatous TM [15, 16, 18, 19] . Using Dextreated TM cells as a model of TM cell dysfunction in glaucoma [12] , we demonstrated that a Wnt signaling inhibitor, 3235-0367, effectively abrogated Dex-induced phenotypes of primary human TM cells. Consistently, we also showed that applying a Wnt signaling activator, BML-284, to the TM cells induced the phenotypes similar to those of Dex-treated TM cells. Our data indicates that Dex-induced TM cell phenotypes are likely caused by aberrant activation of the Wnt signaling pathways. Yuan et al. reported that activation of Wnt signaling with non-canonical Wnt5a induces cross-linked actin networks (CLAN) formation [17] , one of the glaucomatous phenotypes, and that inhibition of Wnt signaling with Ror2 knockdown prevents Dex-mediated CLAN formation [17] . Mao et al. showed that addition of Wnt3A did not seem to have an effect on CLAN formation [16] , suggesting that the non-canonical arm of Wnt signaling is important for CLAN formation. Furthermore, it was shown that Wnt signaling activation by way of myocilin overexpression and application of SB216763, a GSK-3β inhibitor that is able to activate the Wnt/β-catenin signaling pathway in cells [37] , resulted in impaired actin expression of TM cells [38] .
It is known that through the glucocorticoid response element pathway and/or the non-glucocorticoid response element pathway, glucocorticoids can alter expression of hundreds of genes in TM cells [13, 39] . Therefore, a combination of several genes is likely responsible for Wnt signaling activation in the Dex-treated TM cells. Dex also induces myocilin expression in TM cells [40] . Moreover, it has been shown that myocilin is an effective modulator of the Wnt signaling pathways [41] and that overexpression of myocilin in the TM cells activates Wnt signaling [38] . However, because 3235-0367 could effectively abrogate the Dex-induced myocilin expression and BML-284 increased myocilin expression, myocilin expression could be the consequence and not the cause of the initial Wnt signaling activation in the Dex-treated TM cells. Nevertheless, the expression of myocilin in the Dex-treated TM cells could further enhance the activated Wnt signaling.
Wnt signaling is not only a key player in regulating cell fate determination during embryonic development, but also plays critical roles in maintaining tissue homeostasis [33, [42] [43] [44] . It has been shown that Wnt signaling is also important in maintaining TM tissue homeostasis and that suppressing Wnt signaling by constitutively overexpressing Wnt signaling inhibitors such as sFRP1 and Dkk1 in mice can cause damage to the TM tissues [15, 16] . Therefore, we speculate that Dex-induced Wnt signaling activation is a "protective" mechanism of the TM cells. However, to keep the homeostatic state of the TM tissues, the activated Wnt signaling has to be "reset" after an external insult. Therefore, prolonged Dex exposure could persistently activate Wnt signaling that then could lead to abnormal Wnt signaling activation and eventually cause glaucomatous phenotypes. It was shown that sFRP1, a negative Wnt signaling regulator, is upregulated in Dex-treated TM cells [9] and glaucomatous TM tissues [9, 15] . Plausibly, sFRP1 could be the negative feedback system generated by glaucomatous TM cells to suppress the abnormal Wnt signaling in the cells that is similar to that observed in cardiomyocyte differentiation [45] . Indeed, it was also shown that the expression level of DKK1 is also evaluated in the Dex-treated TM cells [9] , and it is known that DKK1 is a target of the canonical Wnt signaling pathway [46] .
Because our study showed that inhibiting the Wnt signaling pathway abrogated Dex-induced phenotypes of primary human TM cells, yet in the presence of Wnt signaling activator BML-284, a phenotype similar to that induced by Dex in the TM cells, we propose that Wnt signaling may exhibit pleiotropic roles in Dex-induced glaucomatous TM. Like other glaucoma risk factors, prolonged steroid treatment may cause abnormal hyperactivity of Wnt signaling; in turn, the abnormal Wnt signaling activation may promote TM cell malfunction and tissue damage that culminates in steroid-induced glaucoma. Therefore, smallmolecule Wnt signaling inhibitors such as 3235-0367 may be helpful in developing a therapeutic target against the aberrant TM cellular activity in steroid-induced glaucoma. Conversely, since Wnt signaling plays an important role in maintaining tissue homeostasis, we speculate that abnormally low Wnt signaling in the TM cells could also cause TM cell dysfunction that leads to glaucomatous phenotypes [16] . In such a case, a small-molecule Wnt signaling activator, such as BML-284, can potentially be used in therapeutic development.
Conclusion
Our study shows that Dex-treated trabecular meshwork cells exhibit increased collagen and fibronectin expression. Wnt signaling inhibitor 3235-0367 can suppress these Dex-induced effects. In contrast, the Wnt signaling activator BML-284 can induce a phenotype similar to that of the Dex-treated TM cells. Taken together, we conclude that Wnt signaling plays an important role in the Dex-mediated impairment of TM cell functions and that the use of small-molecule Wnt signaling inhibitors may provide an opportunity to restore TM cell and tissue in steroid-induced glaucoma.
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